Trends and Updates in the Management and Outcomes of Acute Uncomplicated Type B Aortic Dissection.

Type B aortic dissection (TBAD) presents a complex clinical challenge requiring coordinated, multidisciplinary care to optimize patient outcomes. While rapid intervention is crucial for complicated TBAD, the optimal management of uncomplicated cases remains less well-defined. Historically, uncomplicated TBAD was managed medically, but recent years have seen a shift toward selective interventional approaches. Updated American and European guidelines now recommend thoracic endovascular aortic repair (TEVAR) for high-risk, uncomplicated cases, characterized by factors including a large aortic diameter, large entry tears, or persistent pain. Observations from the International Registry of Acute Aortic Dissection highlight a significant shift toward endovascular management and reduced mortality over time. The ADSORB and INSTEAD-XL trials suggested that pre-emptive TEVAR may benefit certain high-risk patients by promoting favorable aortic remodeling. However, routine use of TEVAR in all uncomplicated cases is presently still controversial due to risks such as stroke and spinal cord ischemia, which emphasize the importance of careful patient selection. Current evidence supports a tailored approach that integrates clinical and imaging risk factors to identify patients most likely to benefit from pre-emptive TEVAR. In addition, ongoing randomized controlled trials, including IMPROVE-AD, SUNDAY, and EARNEST, will hopefully provide critical data on the risks and benefits of TEVAR in uncomplicated TBAD. Moving forward, interdisciplinary collaboration among different medical and engineering specialties, and refined risk stratification will be essential to advance TBAD management, enhancing outcomes for both complicated and uncomplicated cases.